Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: Five-year follow-up of a phase 2 clinical trial
Mené sur 45 patients atteints d'un myélome multiple récemment diagnostiqué (durée de suivi : 5 ans), cet essai de phase II évalue, du point de vue de la rémission complète et de la survie sans progression, l'efficacité d'un traitement combinant carfilzomib, lénalidomide et dexaméthasone
State-of-the art treatment of multiple myeloma (MM) involves induction with triplet-based regimens using combinations of immunomodulatory drugs and proteasome inhibitors, which have shown improved progression-free survival and overall survival compared with doublet regimens in the newly diagnosed (ND) and relapsed and refractory (RR) setting.1-3 Carfilzomib is a selective proteasome inhibitor approved by the US Food and Drug Administration for use in the carfilzomib, lenalidomide, and dexamethasone (KRd) regimen for the treatment of RRMM.3,4 We previously reported early data on this phase 2 study of 45 patients with NDMM.5 Herein, we expand on our initial results and present the long-term durability of minimal residual disease–negative complete remissions (MRD-negative CRs) and time to progression, the last characterized by depth of response, age, and cytogenetic risk profile.
JAMA Oncology 2018